2015 APHA Annual Meeting & Expo

Home Events & Meetings Annual Meeting Schedule & Program

Recorded Annual Meeting Presentations (RAMP) are now available for purchase.
Only $90 for presenters, $140 for registered attendees and $200 for non-attendees.

Online Program

330280
A comparison of participant's satisfaction with injectable diacetylmorphine and hydromorphone treatment in a double-blind randomized controlled trial for the treatment of long-term opioid dependence


Sunday, November 1, 2015

Kirsten Marchand, PhD Candidate, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Daphne Guh, MSc, Centre for Health Evaluation and Outcome Sciences, BC, Canada
Scott MacDonald, MD, Providence Health Care, Crosstown Clinic, Vancouver BC, BC, Canada
Scott Harrison, MA, School of Nursing, University of British Columbia, Vancouver, BC, Canada
Suzanne Brissette, MD, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, QC, Canada
Martin Schechter, MD, PhD, School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
Eugenia Oviedo-Joekes, PhD, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Satisfaction with addiction treatment is associated with positive treatment outcomes. SALOME (Study to Assess Longer-term Opioid Medication Effectiveness) is a double-blind, phase III, non-inferiority randomized controlled trial testing the effectiveness of injectable diacetylmorphine (active ingredient in heroin) and hydromorpone (licensed pain medication) for long-term heroin injectors not benefitting from available treatments. This study aims to test factors associated with satisfaction after six-months of treatment.  

A total of 202 long-term opioid dependent men and women in Vancouver, Canada were randomly assigned. At 6-months follow-up, participants completed the Client Satisfaction Questionnaire (CSQ) and additional data on sociodemographic, drug use and retention to treatment. The CSQ ranges from 8-32; higher scores indicate higher satisfaction. Bivariate and multivariate analyses (in progress) were used to determine predictors of treatment satisfaction.

At the 6-months follow-up, 194 (96.0%) participants completed the CSQ. Participants in both treatment groups were highly satisfied with treatment (overall mean satisfaction score=28.3; standard deviation=4.1) with no significant differences by treatment group (p=0.40). Preliminary results indicate that satisfaction with treatment was not associated with participant’s age (p=0.577), gender (p=0.404) or ethnicity (p=0.83). However, participants retained to treatment (p<0.001) and with lower use of illicit heroin (p<0.001) had significantly higher mean satisfaction scores.

Preliminary findings indicate that participants randomized to receive innovative injectable treatments were highly satisfied. Satisfaction was also positively associated with injectable treatment retention and illicit heroin use. The findings further emphasize the value of engaging patients in evaluations of received treatments for improving patient success.

Learning Areas:

Public health or related research

Learning Objectives:
Evaluate satisfaction with injectable opioid treatment for treatment refractory chronic heroin injectors.

Keyword(s): Drug Abuse Treatment, Patient Satisfaction

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Kirsten Marchand is a PhD candidate at the University of British Columbia's School of Population and Public Health and was the research coordinator for the Gender Matters study, data from which will be presented.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 2057.0: International perspectives on substance use and health outcomes